CSL Statutory Accounts for the Half Year Ended 31 Dec 2024
Filed with ASX · · 27 pages · English
These documents should be read in conjunction with the CSL Limited 2024 Annual Report (accessible in the “Investor” section of CSL.com). Authorised for lodgement by: Fiona Mead Company Secretary For further information, please contact: Investors: Chris Cooper Head, Investor Relations CSL Limited P: +61 455 022 740 E: [email protected] Bernard Ronchi Director, Investor Relations CSL Limited P
Earlier from CSL
- Results Presentation
- Results Announcement
- Full Year Statutory Accounts for 30 June 2024
- Half Year Results Investor Presentation
- Statutory Accounts for the Half Year Ended 31 December 2023
Later from CSL
- CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
- CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
- England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
- U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
- Health Canada Has Authorized CSL's ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)
Follow CSL into a list and get an email when it puts out news.
Follow CSL